JAKARTA, Indonesia, June 25, 2025 /PRNewswire/ -- PT Bank Rakyat Indonesia (Persero) Tbk, (IDX: BBRI) has officially issued its first Sustainable Social Bond Phase I Year 2025, valued at IDR 5 trillion. The issuance received strong interest with an oversubscription of IDR 6.57 trillion—1.31 times the initial target.
This bond is part of BRI's Sustainable Public Offering Program I, which aims to raise a total of IDR 20 trillion. With this issuance, BRI becomes the first bank in Indonesia to issue a Social Bond.
The agreement signing was attended by BRI President Director Hery Gunardi, Director of Treasury & International Banking Farida Thamrin, Director of Operations Hakim Putratama, joint lead underwriters, and supporting institutions.
BRI President Director Hery Gunardi explained that the bank's decision to issue a Social Bond stems from the limited availability of socially focused securities instruments in Indonesia. "This also serves as concrete proof of BRI's commitment to maintaining ESG-oriented financing," said Hery.
He further stated that the Social Bond issuance is aligned with the bank's strategy to strengthen its funding structure through the diversification of wholesale-based funding sources. "This move also serves as part of the company's strategy to broaden access to more competitive and sustainable capital markets," he added.
The bond has received a Triple A (idAAA) rating from the Indonesian credit rating agency PEFINDO and is offered in three series:
Series A: 2-year tenor with a fixed interest rate of 6.45% per annum
Series B: 3-year tenor with a fixed interest rate of 6.55% per annum
Series C: 5-year tenor with a fixed interest rate of 6.60% per annum
Issued through a bookbuilding process, the bond involves prominent underwriters including PT BRI Danareksa Sekuritas, PT Trimegah Sekuritas Indonesia Tbk, PT Mandiri Sekuritas, PT DBS Vickers Sekuritas Indonesia, PT Indo Premier Sekuritas, and PT Bahana Sekuritas. The Social Framework was developed with ESG Coordinator Bank DBS Indonesia.
The bond will be listed on the Indonesia Stock Exchange (IDX) and registered with KSEI. Coupon payments will be made quarterly, with a full principal repayment (bullet payment) at maturity.
Hery concluded that this issuance reinforces BRI's commitment to expanding financial inclusion and empowering communities through sustainable financing.
For more information about BANK BRI, visit www.bri.co.id
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BRI Becomes First in Indonesia to Issue IDR 5 Trillion Social Bond to Support Inclusive, Sustainable Financing
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
